FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W156988113> ?p ?o ?g. }

• W156988113 endingPage "2061" @default.
• W156988113 startingPage "2054" @default.
• W156988113 abstract "Abstract Human recombinant interleukin-3 (IL-3; Sandoz AG, Basel, Switzerland) was administered for 7 days to patients with neoplastic disease and normal hematopoiesis. The purpose of the study was to assess IL-3 toxicity, to identify target cells, to define their kinetics of response at different dose levels, and to determine if IL-3 in vivo increased the sensitivity of bone marrow (BM) progenitors to the action of other hematopoietic growth factors. A total of 21 patients entered the study; the dosage ranged from 0.25 to 10 micrograms/kg/d. The effect on peripheral blood cells during treatment showed no significant changes in the number of platelets, erythrocytes, neutrophils, or lymphocytes (and their subsets). A mild monocytosis and basophilia occurred. Eosinopenia, present in the first hours of treatment, was followed by a dose-and time-dependent eosinophilia. IL-3 treatment affected BM cell proliferation by increasing the percentage of BM progenitors engaged in the S-phase of the cell cycle. The effect was dose dependent, with the various progenitors showing different degrees of sensitivity. The most sensitive progenitors were the megakaryocyte progenitors (colony-forming unit-megakaryocyte), then the erythroid progenitors (burst-forming unit-erythroid), and finally the granulo- monocyte progenitors (colony-forming unit-granulocyte-macrophage) whose proliferative activity was stimulated at the higher doses of IL-3. Only a slight increase in the proliferative activity of myeloblasts, promyelocytes, and myelocytes was observed, whereas the activity of erythroblasts was unchanged. The priming effect was such that BM progenitors, purified from patients treated with IL-3, produced more colonies in vitro in the presence of granulocyte colony-stimulating factor (G-CSF; granulocyte colonies), IL-5 (eosinophil colonies), and granulocyte-macrophage CSF (GM-CSF; predominantly eosinophil colonies). These data indicate that even in vivo IL-3 acts essentially as a primer for the action of other cytokines. Therefore, optimum stimulus of myelopoiesis will require either endogenous or exogenous late-acting cytokines such as G-CSF, erythropoietin, GM-CSF, and IL-6 for achieving fully mature cells in peripheral blood. If exogenous cytokines are used with IL-3, it is likely that G-CSF will yield more neutrophils, whereas GM-CSF may enhance eosinophils, monocytes, and neutrophils. Attention to the clinical relevance of each cell type will be necessary and should determine the selection of the combination of cytokines." @default.
• W156988113 created "2016-06-24" @default.
• W156988113 creator A5007181674 @default.
• W156988113 creator A5009389934 @default.
• W156988113 creator A5012373998 @default.
• W156988113 creator A5014664627 @default.
• W156988113 creator A5017619486 @default.
• W156988113 creator A5034462076 @default.
• W156988113 creator A5041574361 @default.
• W156988113 creator A5044390662 @default.
• W156988113 creator A5080179300 @default.
• W156988113 creator A5081018862 @default.
• W156988113 date "1993-10-01" @default.
• W156988113 modified "2023-09-27" @default.
• W156988113 title "Interleukin-3 in vivo: kinetic of response of target cells" @default.
• W156988113 cites W1480923577 @default.
• W156988113 cites W1549719455 @default.
• W156988113 cites W1565595794 @default.
• W156988113 cites W1601467148 @default.
• W156988113 cites W1825082566 @default.
• W156988113 cites W1974761303 @default.
• W156988113 cites W1976133490 @default.
• W156988113 cites W2037382362 @default.
• W156988113 cites W2046188084 @default.
• W156988113 cites W2062729668 @default.
• W156988113 cites W2068499309 @default.
• W156988113 cites W2071595697 @default.
• W156988113 cites W2097710494 @default.
• W156988113 cites W2123296224 @default.
• W156988113 cites W2149894706 @default.
• W156988113 cites W2154758405 @default.
• W156988113 cites W2159619345 @default.
• W156988113 cites W2261504327 @default.
• W156988113 cites W2336868589 @default.
• W156988113 cites W2425605911 @default.
• W156988113 cites W281852963 @default.
• W156988113 cites W297611589 @default.
• W156988113 cites W39322402 @default.
• W156988113 cites W640065259 @default.
• W156988113 cites W68002947 @default.
• W156988113 doi "https://doi.org/10.1182/blood.v82.7.2054.2054" @default.
• W156988113 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8400256" @default.
• W156988113 hasPublicationYear "1993" @default.
• W156988113 type Work @default.
• W156988113 sameAs 156988113 @default.
• W156988113 citedByCount "42" @default.
• W156988113 countsByYear W1569881132012 @default.
• W156988113 countsByYear W1569881132013 @default.
• W156988113 countsByYear W1569881132021 @default.
• W156988113 countsByYear W1569881132022 @default.
• W156988113 crossrefType "journal-article" @default.
• W156988113 hasAuthorship W156988113A5007181674 @default.
• W156988113 hasAuthorship W156988113A5009389934 @default.
• W156988113 hasAuthorship W156988113A5012373998 @default.
• W156988113 hasAuthorship W156988113A5014664627 @default.
• W156988113 hasAuthorship W156988113A5017619486 @default.
• W156988113 hasAuthorship W156988113A5034462076 @default.
• W156988113 hasAuthorship W156988113A5041574361 @default.
• W156988113 hasAuthorship W156988113A5044390662 @default.
• W156988113 hasAuthorship W156988113A5080179300 @default.
• W156988113 hasAuthorship W156988113A5081018862 @default.
• W156988113 hasBestOaLocation W1569881131 @default.
• W156988113 hasConcept C109159458 @default.
• W156988113 hasConcept C131665280 @default.
• W156988113 hasConcept C16685009 @default.
• W156988113 hasConcept C201750760 @default.
• W156988113 hasConcept C203014093 @default.
• W156988113 hasConcept C2776090121 @default.
• W156988113 hasConcept C2779705218 @default.
• W156988113 hasConcept C2780007613 @default.
• W156988113 hasConcept C2781087989 @default.
• W156988113 hasConcept C28328180 @default.
• W156988113 hasConcept C71924100 @default.
• W156988113 hasConcept C79484868 @default.
• W156988113 hasConcept C86803240 @default.
• W156988113 hasConcept C8891405 @default.
• W156988113 hasConcept C95444343 @default.
• W156988113 hasConceptScore W156988113C109159458 @default.
• W156988113 hasConceptScore W156988113C131665280 @default.
• W156988113 hasConceptScore W156988113C16685009 @default.
• W156988113 hasConceptScore W156988113C201750760 @default.
• W156988113 hasConceptScore W156988113C203014093 @default.
• W156988113 hasConceptScore W156988113C2776090121 @default.
• W156988113 hasConceptScore W156988113C2779705218 @default.
• W156988113 hasConceptScore W156988113C2780007613 @default.
• W156988113 hasConceptScore W156988113C2781087989 @default.
• W156988113 hasConceptScore W156988113C28328180 @default.
• W156988113 hasConceptScore W156988113C71924100 @default.
• W156988113 hasConceptScore W156988113C79484868 @default.
• W156988113 hasConceptScore W156988113C86803240 @default.
• W156988113 hasConceptScore W156988113C8891405 @default.
• W156988113 hasConceptScore W156988113C95444343 @default.
• W156988113 hasIssue "7" @default.
• W156988113 hasLocation W1569881131 @default.
• W156988113 hasOpenAccess W156988113 @default.
• W156988113 hasPrimaryLocation W1569881131 @default.
• W156988113 hasRelatedWork W2015740105 @default.
• W156988113 hasRelatedWork W2044531392 @default.

• next